| Literature DB >> 26458943 |
Joyce Obeid1,2, Thanh Nguyen3,4, Tania Cellucci5,6, Maggie J Larché7,8, Brian W Timmons9,10.
Abstract
BACKGROUND: Youth with juvenile idiopathic arthritis (JIA) may be at risk of poor cardiovascular health. Circulating endothelial progenitor cells (EPCs) and circulating endothelial cells (CECs) are markers of cardiovascular repair and damage, respectively, and respond to exercise. The objectives of this study were to compare resting levels of EPCs and CECs in JIA and controls, and to assess the effects of distinct types of exercise on EPCs and CECs in JIA and controls.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26458943 PMCID: PMC4604015 DOI: 10.1186/s12969-015-0038-4
Source DB: PubMed Journal: Pediatr Rheumatol Online J ISSN: 1546-0096 Impact factor: 3.054
Disease-related characteristics of children with JIA
| Age (sex) | JIA type | Disease duration (years) | CRP | ESR | Active joints | Medications | |
|---|---|---|---|---|---|---|---|
| I | 12.8 (F) | Psoriatic | 3.8 | 0.34 | 6.0 | Wrists | NSAID |
| II | 10.8 (M) | Systemic | 6.0 | 0.05a | n/a | None | None |
| III | 17.4 (M) | Oligoarthritis (ANA-, RF+) | 14.2 | 0.75a | 6.0 | None | None |
| IV | 13.8 (M) | Polyarthritis (ANA-, RF-) | 3.6 | 2.80 | 11.0 | None | Methotrexate |
| V | 11.1 (F) | Polyarthritis (ANA-, RF+) | 3.6 | 0.90 | 15.0 | Ankles | Methotrexate, Corticosteroid |
| VI | 11.5 (F) | Polyarthritis (ANA-, RF-) | 7.3 | <0.20 | 9.0 | None | Methotrexate |
| VII | 16.5 (F) | Oligoarthritis (ANA+, RF-) | 15.2 | n/a | n/a | None | NSAID |
ANA Antinuclear Antibody, CRP C-Reactive Protein, ESR Erythrocyte Sedimentation Rate, n/a not available, NSAID Non-Steroidal Anti-Inflammatory Drugs, RF Rheumatoid Factor. Disease duration was calculated as the date of confirmed diagnosis of arthritis to date of enrollment in the study. CRP values were based on a blood sample taken at the clinic visit closest to study participation (a CRP was measured from a study visit blood sample since participants did not have any recent clinic visits). Active Joints refer to joints assessed as tender or swollen by the participant’s rheumatologist at the clinic visit closest to study participation. Medications refer to those taken regularly by the participant at the time of study completion (Off medication duration: II = 5.0 years, and III = 0.9 years)
Participant characteristics by group
| JIA | Control | Mean difference (Lower, Upper 95 % CI) | P value | Effect size | |
|---|---|---|---|---|---|
| N (Males) | 7 (3) | 6 (1) | n/a | n/a | n/a |
| Age (years) | 13.4 ± 2.6 | 14.0 ± 2.3 | −0.6 (-3.8, 2.6) | 0.67 | 0.26 |
| Height (cm) | 157.5 ± 15.0 | 162.1 ± 5.2 | −4.6 (-20.4, 11.1) | 0.53 | 0.88 |
| Weight (kg) | 56.0 ± 16.7 | 50.1 ± 7.1 | 5.9 (-11.9, 23.8) | 0.48 | 0.83 |
|
| 45.6 ± 11.4 | 57.9 ± 8.3 | −12.4 (-25.7, 1.0) | 0.07 | 1.48 |
|
| 3.0 ± 1.0 | 3.5 ± 0.5 | −0.4 (-1.5, 0.7) | 0.43 | 1.00 |
| MVPA (min/d) | 35.7 ± 13.0 | 26.1 ± 9.7 | 9.6 (-6.3, 25.5) | 0.21 | 0.99 |
| MVPA (min/hr wear time) | 4.4 ± 2.0 | 3.8 ± 1.9 | 0.6 (-2.0, 3.3) | 0.61 | 0.32 |
maximal volume of oxygen consumed over 30-sec during the aerobic fitness test, W peak workload achieved during the aerobic fitness test, MVPA moderate-to-vigorous physical activity. Mean difference calculated as JIA – control. Statistical significance set at p ≤ 0.05
Resting EPC and CEC concentrations in JIA (n = 7) and Controls (n = 5)
| JIA | Controls | Effect size | |||
|---|---|---|---|---|---|
| MICE | HIIE | MICE | HIIE | ||
| EPC | |||||
| % of PBMCs | 0.02 ± 0.02 | 0.02 ± 0.02 | 0.03 ± 0.02 | 0.02 ± 0.01 | 0.25 |
| (0.004, 0.03) | (0.003, 0.04) | (0.01, 0.05) | (0.003, 0.05) | ||
| × 106 cells/L | 0.55 ± 0.48 | 0.55 ± 0.50 | 0.91 ± 0.55 | 0.79 ± 0.42 | 0.55 |
| (0.10, 0.99) | (0.03, 1.08) | (0.22, 1.60) | (0.24, 1.83) | ||
| CEC | |||||
| % of PBMCs | 0.23 ± 0.26 | 0.11 ± 0.13 | 0.20 ± 0.23 | 0.22 ± 0.22 | 0.17 |
| (0.01, 0.46) | (0.03, 0.24) | (0.09, 0.48) | (0.33, 0.77) | ||
| × 106 cells/L | 6.36 ± 9.61 | 2.85 ± 3.19 | 6.28 ± 7.24 | 8.26 ± 8.88 | 0.37 |
| (2.52, 15.24) | (0.49, 6.20) | (2.71, 15.28) | (13.81, 30.3) | ||
Data are presented as mean ± SD (lower, upper 95 % CI). Effect size calculated in JIA vs. controls, standardized to the pooled SD of the control group
Fig. 1REST, MID- and POST-exercise proportions EPCs and CECs in youth with JIA (n = 7) and healthy controls (n = 5). A significant interaction was seen for EPCs as a proportion of PBMCs during MICE (a), whereby healthy controls demonstrated an increase in EPCs while EPCs in JIA remained unchanged. Conversely, HIIE (b) did not alter EPCs in healthy controls or JIA. Similarly, neither MICE (c) nor HIIE (d) had any effect on CECs in JIA and healthy controls. * significant difference from REST, p = 0.05; a significant difference between JIA and healthy controls, p = 0.05; b significant difference between JIA and healthy controls, p <0.01